{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:48:28Z","timestamp":1787287708072,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020439","name":"Jiangsu Pharmaceutical Association","doi-asserted-by":"crossref","award":["A202428"],"award-info":[{"award-number":["A202428"]}],"id":[{"id":"10.13039\/100020439","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Vlove Charity Foundation","award":["214185"],"award-info":[{"award-number":["214185"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-13396-3","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T23:04:01Z","timestamp":1753830241000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["LC-MS\/MS quantification of omadacycline in human plasma for therapeutic drug monitoring: method development and clinical application"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4955-0859","authenticated-orcid":false,"given":"Yueyuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunli","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"issue":"18","key":"13396_CR1","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s40265-018-1015-2","volume":"78","author":"A Markham","year":"2018","unstructured":"Markham, A. & Keam, S. J. Omadacycline: first global approval. Drugs 78 (18), 1931\u20131937 (2018).","journal-title":"Drugs"},{"issue":"2","key":"13396_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/ph12020063","volume":"12","author":"F Dur\u00e3es","year":"2019","unstructured":"Dur\u00e3es, F. & Sousa, E. Omadacycline: a newly approved antibacterial from the class of tetracyclines. Pharmaceuticals 12 (2), 63 (2019).","journal-title":"Pharmaceuticals"},{"issue":"7","key":"13396_CR3","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s10096-020-04121-1","volume":"41","author":"S Yaghoubi","year":"2022","unstructured":"Yaghoubi, S. et al. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. Eur J Clin Microbiol Infect Dis. 41 (7), 1003\u20131022 (2022).","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"9","key":"13396_CR4","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1128\/AAC.01135-17","volume":"61","author":"MH Gotfried","year":"2017","unstructured":"Gotfried, M. H. et al. Comparison of Omadacycline and Tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects. Antimicrob. Agents Chemother. 61 (9), 1135\u20131117. https:\/\/doi.org\/10.1128\/AAC.01135-17 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"13396_CR5","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1128\/AAC.02057-17","volume":"62","author":"JK Berg","year":"2018","unstructured":"Berg, J. K. et al. Pharmacokinetics and safety of Omadacycline in subjects with impaired renal function. Antimicrob Agents Hemother. 62 (2), 2057\u20132017. https:\/\/doi.org\/10.1128\/AAC.02057-17 (2018).","journal-title":"Antimicrob Agents Hemother"},{"issue":"11","key":"13396_CR6","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1128\/AAC.01650-20","volume":"64","author":"SJ Kovacs","year":"2020","unstructured":"Kovacs, S. J. et al. An open-label study of the impact of hepatic impairment on the pharmacokinetics and safety of single oral and intravenous doses of Omadacycline. Antimicrob Agents Chemother. 64 (11), 1650\u20131620. https:\/\/doi.org\/10.1128\/AAC.01650-20 (2020).","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"13396_CR7","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.clinthera.2024.06.014","volume":"46","author":"A Zhang","year":"2024","unstructured":"Zhang, A. et al. Physiologically based Pharmacokinetic model for predicting Omadacycline Pharmacokinetics and pharmacodynamics in healthy and hepatic impairment populations. Clin Ther. 46 (8), 629\u2013635 (2024).","journal-title":"Clin Ther"},{"issue":"4","key":"13396_CR8","doi-asserted-by":"publisher","first-page":"239721","DOI":"10.1128\/aac.02397-21","volume":"67","author":"M Trang","year":"2023","unstructured":"Trang, M. et al. Evaluation of the impact of comorbidities on Omadacycline pharmacokinetics. Antimicrob Agents Chemother. 67 (4), 239721. https:\/\/doi.org\/10.1128\/aac.02397-21 (2023).","journal-title":"Antimicrob Agents Chemother"},{"key":"13396_CR9","doi-asserted-by":"publisher","first-page":"106713","DOI":"10.1016\/j.ejps.2024.106713","volume":"195","author":"K Wang","year":"2024","unstructured":"Wang, K. et al. Evaluation of Omadacycline dosing regimens in Chinese using population pharmacokinetic-pharmacodynamic analysis. Eur J Pharm Sci. 195, 106713 (2024).","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"13396_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/14787210.2020.1696192","volume":"18","author":"F Annoni","year":"2020","unstructured":"Annoni, F., Grimaldi, D. & Taccone, F. S. Individualized antibiotic therapy in the treatment of severe infections. Expert Rev Anti Infect Ther. 18 (1), 27\u201335 (2020).","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"4","key":"13396_CR11","doi-asserted-by":"publisher","first-page":"R126","DOI":"10.1186\/cc9091","volume":"14","author":"FS Taccone","year":"2010","unstructured":"Taccone, F. S. et al. Insufficient \u03b2-lactam concentrations in the early phase of severe sepsis and septic shock. Critical Care. 14 (4), R126 (2010).","journal-title":"Critical Care"},{"issue":"9","key":"13396_CR12","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1128\/AAC.02534-17","volume":"62","author":"A Jacobs","year":"2018","unstructured":"Jacobs, A. et al. \u03b2-Lactam dosage regimens in septic patients with augmented renal clearance. Antimicrob Agents Chemother. 62 (9), 2534\u20132517. https:\/\/doi.org\/10.1128\/AAC.02534-17 (2018).","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"13396_CR13","doi-asserted-by":"publisher","first-page":"R105","DOI":"10.1186\/cc13886","volume":"18","author":"M Beumier","year":"2014","unstructured":"Beumier, M. et al. \u03b2-Lactam antibiotic concentrations during continuous renal replacement therapy. Critical Care. 18 (3), R105 (2014).","journal-title":"Critical Care"},{"issue":"2","key":"13396_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/00003246-200102000-00030","volume":"29","author":"C Joukhadar","year":"2001","unstructured":"Joukhadar, C. et al. Impaired target site penetration of beta-lactams May account for therapeutic failure in patients with septic shock. Critical Care Medicine. 29 (2), 385\u2013391 (2001).","journal-title":"Critical Care Medicine"},{"issue":"3","key":"13396_CR15","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ijantimicag.2014.11.005","volume":"45","author":"K Donadello","year":"2015","unstructured":"Donadello, K. et al. \u03b2-Lactam pharmacokinetics during extracorporeal membrane oxygenation therapy: A case-control study. Int J Antimicrob Agents. 45 (3), 278\u2013282 (2015).","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"13396_CR16","doi-asserted-by":"publisher","first-page":"4788","DOI":"10.1002\/jms.4788","volume":"56","author":"VP Gaspar","year":"2021","unstructured":"Gaspar, V. P., Ibrahim, S., Zahedi, R. P. & Borchers, C. H. Utility, promise, and limitations of liquid chromatography-mass spectrometry-based therapeutic drug monitoring in precision medicine. J Mass Spectrom. 56 (11), 4788. https:\/\/doi.org\/10.1002\/jms.4788 (2021).","journal-title":"J Mass Spectrom"},{"issue":"8","key":"13396_CR17","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1080\/00498254.2016.1213465","volume":"47","author":"J Flarakos","year":"2017","unstructured":"Flarakos, J. et al. Clinical disposition, metabolism and in vitro drug-drug interaction properties of Omadacycline. Xenobiotica 47 (8), 682\u2013696 (2017).","journal-title":"Xenobiotica"},{"key":"13396_CR18","doi-asserted-by":"publisher","first-page":"107503","DOI":"10.1016\/j.vascn.2024.107503","volume":"127","author":"G Suhang","year":"2024","unstructured":"Suhang, G. et al. Development, validation, and clinical application of a UPLC-MS\/MS method for Omadacycline determination in human serum. J Pharmacol Toxicol Methods. 127, 107503 (2024).","journal-title":"J Pharmacol Toxicol Methods"},{"key":"13396_CR19","doi-asserted-by":"publisher","first-page":"124057","DOI":"10.1016\/j.jchromb.2024.124057","volume":"1236","author":"C Hu","year":"2024","unstructured":"Hu, C., Wang, W., Jo, J. & Garey, K. W. Development and validation of LC-MS\/MS for quantifying Omadacycline from stool for gut Microbiome studies. J Chromatogr B Analyt Technol Biomed Life Sci. 1236, 124057 (2024).","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"13396_CR20","doi-asserted-by":"publisher","first-page":"869237","DOI":"10.3389\/fphar.2022.869237","volume":"13","author":"H Yang","year":"2022","unstructured":"Yang, H. et al. Pharmacokinetics, safety and pharmacokinetics\/pharmacodynamics analysis of Omadacycline in Chinese healthy subjects. Front Pharmacol. 13, 869237 (2022).","journal-title":"Front Pharmacol"},{"issue":"3","key":"13396_CR21","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/jcph.814","volume":"57","author":"E Tzanis","year":"2017","unstructured":"Tzanis, E. et al. Effect of food on the bioavailability of Omadacycline in healthy participants. J Clin Pharmacol. 57 (3), 321\u2013327 (2017).","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"13396_CR22","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1128\/AAC.02368-16","volume":"61","author":"AJ Lepak","year":"2017","unstructured":"Lepak, A. J., Zhao, M., Marchillo, K., VanHecker, J. & Andes, D. R. In vivo pharmacodynamic evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the murine pneumonia model. Antimicrob Agents Chemother. 61 (5), 2368\u20132316. https:\/\/doi.org\/10.1128\/AAC.02368-16 (2017).","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"13396_CR23","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1093\/cid\/ciz309","volume":"69","author":"KA Rodvold","year":"2019","unstructured":"Rodvold, K. A. & Pai, M. P. Pharmacokinetics and pharmacodynamics of oral and intravenous Omadacycline. Clin Infect Dis. 69 (Suppl 1), S16\u2013S22 (2019).","journal-title":"Clin Infect Dis"},{"key":"13396_CR24","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1128\/AAC.00624-19","volume":"63(7)","author":"AJ Lepak","year":"2019","unstructured":"Lepak, A. J., Zhao, M., Marchillo, K., VanHecker, J. & Andes, D. R. In vivo pharmacodynamics of Omadacycline against Staphylococcus aureus in the neutropenic murine thigh infection model. Antimicrob. Agents Chemother. 63(7), 624\u2013619. https:\/\/doi.org\/10.1128\/AAC.00624-19 (2019).","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13396-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13396-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13396-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T07:10:34Z","timestamp":1757315434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13396-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13396"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-13396-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of the Second Affiliated Hospital of Soochow University (Ethics Approval Number: JD-LK2024171-IR01).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We further confirm that the content has not been published or submitted for publication elsewhere.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"27728"}}